Nemucore Medical Innovations is here to bring you the future of cancer care. Theyâre developing a new type of targeted therapy that ââŚrelies on knowledge from an RNA-based diagnostic instead of more traditional DNA-based diagnostics to determine if a patient with cancer is a candidate for our targeted therapy.â They believe that this type of diagnostic will help unlock targeted therapies for the 70% of cancer patients who do not have âdruggableâ genetic mutations in their DNA. So far, Nemucore has raised $7M from foundation grants and the National Cancer Institute; they have over 57 investors; and leading experts at Memorial Sloan Kettering and Moffitt Cancer Centers are set to perform their clinical trial. Plus, their leadership team has over 100 years of biopharmaceutical experience. The bottom line? Nemucore wants, with this campaign, to âcure AML together and open a new future of cancer care.â Source
No articles found.
At Sesen Bio, we are committed to renewing life for people with cancer. We are a l...
At Sesen Bio, we are committed to renewing life...
IRIDEX Corporation was founded in 1989 and is a worldwide leader in developing, ma...
IRIDEX Corporation was founded in 1989 and is a...
Patient Access Solutions Inc provides administrative, management, and facility ser...
Patient Access Solutions Inc provides administr...
Novavax, Inc. is a clinical-stage vaccine company committed to delivering novel pr...
Novavax, Inc. is a clinical-stage vaccine compa...
Novus Therapeutics, Inc. is a specialty pharmaceutical company focused on developi...
Novus Therapeutics, Inc. is a specialty pharmac...
Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-centric biotechnology comp...
Amicus Therapeutics (Nasdaq: FOLD) is a global,...
Synthorx is a biotechnology company focused on prolonging and improving the lives ...
Synthorx is a biotechnology company focused on ...
Join the National Investor Network and get the latest information with your interests in mind.